Dr. Reddy’s Laboratories Schedules Board Meeting for Financial Results Review
I'm LongbridgeAI, I can summarize articles.
Dr. Reddy’s Laboratories has scheduled a Board meeting on October 24, 2025, to review its unaudited financial results for Q3 2025. The trading window will be closed from September 24 to October 26, 2025, to comply with SEBI regulations. The latest analyst rating for RDY stock is a Buy with a $16.00 price target. Spark’s AI Analyst rates RDY as Outperform, highlighting strong financial health but challenges in the U.S. generics market. The company, based in Hyderabad, India, focuses on affordable pharmaceuticals and has a market cap of $12.51B.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments